ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer (ARMOR1)

September 2, 2020 updated by: LTN PHARMACEUTICALS, INC.

ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer

The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
49

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90095
        • UCLA
      • San Bernardino, California, United States, 92404
        • San Bernardino Urological Associates
    • Maryland
      • Baltimore, Maryland, United States, 21231
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Dana Farber Cancer Institute
    • Nevada
      • Las Vegas, Nevada, United States, 89169
        • Comprehensive Cancer Centers of Nevada & US Oncology Research
    • New York
      • Buffalo, New York, United States, 14263
        • Roswell Park Cancer Institute
    • South Carolina
      • Greenville, South Carolina, United States, 29605
        • Greenville Hospital System University Medical Center
    • Washington
      • Seattle, Washington, United States, 98136
        • University of Washington/Seattle Cancer Care Alliance

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Signed informed consent form
  • Confirmed cancer of the prostate
  • Progressing disease in spite of androgen ablation therapy
  • Able to swallow multiple capsules

Exclusion Criteria:

  • Participation in another clinical trial < 4 weeks prior to enrollment

  • Metastatic disease with one or more of the following:

    • Liver involvement
    • Bone pain associated with confirmed evidence of metastases
    • Non-hepatic visceral involvement

  • The following medications:

    • Prior treatment with MDV3100, abiraterone, Provenge or TAK700
    • Prior treatment with ketoconazole
    • Prior treatment with chemotherapy
    • Prior radiation therapy completed ≤ 4 weeks prior to enrollment

  • The following medical conditions:

    • Active angina pectoris
    • History of Hepatitis B or Hepatitis C
    • Known HIV infection
    • Ongoing hypertension

Note: There are additional inclusion and exclusion criteria. The clinical site center will determine if you are eligible. If you are not eligible for the trial, site staff will detail the reasons to you.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: 650 mg TOK-001
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8
Experimental: 1300 mg TOK-001
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8
Experimental: 1950 mg TOK-001
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8
Experimental: 975 mg TOK-001
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8
Experimental: 975 mg TOK-001, supplement
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8
Experimental: 1950 mg TOK-001, split dose
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8
Experimental: 2600 mg TOK-001
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8
Experimental: 2600 mg TOK-001, split dose
Drug: TOK-001
2 capsules (325 mg each), once per day
Other Names:
  • Dose Group 1
Drug: TOK-001
4 capsules (325 mg each), once per day
Other Names:
  • Dose Group 3
Drug: TOK-001
6 capsules (325 mg each), once per day
Other Names:
  • Dose Group 4
Drug: TOK-001
3 capsules (325 mg each), once per day
Other Names:
  • Dose Group 2
Drug: TOK-001
3 capsules (325 mg each), once per day with supplement
Other Names:
  • Dose Group 5
Drug: TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Other Names:
  • Dose Group 6
Drug: TOK-001
8 capsules (325 mg each), once per day
Other Names:
  • Dose Group 7
Drug: TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Other Names:
  • Dose Group 8

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Phase 1: Incidence of adverse events
Time Frame: 3 months
Safety will be assessed by incidence of AEs and change from baseline in the following additional safety parameters: clinical laboratory assessments, physical examination, vital signs, and 12 lead electrocardiograms (ECGs)
3 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Efficacy Measures
Time Frame: 3 months
Efficacy will be assessed by evaluation of change in PSA level, changes from baseline in CT/MRI and bone scans, response rate RECIST criteria and additional special laboratories
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
LTN PHARMACEUTICALS, INC.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: R. B. Montgomery, MD, University of Washington
  • Principal Investigator: M. E. Taplin, MD, Dana-Farber Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2009

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2011

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2012

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 14, 2009

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 14, 2009

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 17, 2009

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 4, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 2, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TOK-200-05

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings